Hamilton cycles in quasirandom hypergraphs

We show that, for a natural notion of quasirandomness in $k$-uniform hypergraphs, any quasirandom $k$-uniform hypergraph on $n$ vertices with constant edge density and minimum vertex degree $\Omega(n^{k-1})$ contains a loose Hamilton cycle. We also give a construction to show that a $k$-uniform hypergraph satisfying these conditions need not contain a Hamilton $\ell$-cycle if $k-\ell$ divides $k$. The remaining values of $\ell$ form an interesting open question.Comment: 18 pages. Accepted for publication in Random Structures & Algorithm

Supporting the Production of High-Quality Data in Concurrent Plant Engineering Using a MetaDataRepository

In recent years, several process models for data quality management have been proposed. As data quality problems are highly application-specific, these models have to remain abstract. This leaves the question of what to do exactly in a given situation unanswered. The task of implementing a data quality process is usually delegated to data quality experts. To do so, they rely heavily on input from domain experts, especially regarding data quality rules. However, in large engineering projects, the number of rules is very large and different domain experts might have different data quality needs. This considerably complicates the task of the data quality experts. Nevertheless, the domain experts need quality measures to support their decision-making process what data quality problems to solve most urgently. In this paper, we propose a MetaDataRepository architecture which allows domain experts to model their quality expectations without the help from technical experts. It balances three conflicting goals: non-intrusiveness, simple and easy usage for domain experts and sufficient expressive power to handle most common data quality problems in a large concurrent engineering environment

Healthcare Process Support: Achievements, Challenges, Current Research

Healthcare organizations are facing the challenge of delivering high-quality services to their patients at affordable costs. To tackle this challenge, the Medical Informatics community targets at formalisms for developing decision-support systems (DSSs) based on clinical guidelines. At the same time, business process management (BPM) enables IT support for healthcare processes, e.g., based on workflow technology. By integrating aspects from these two fields, promising perspectives for achieving better healthcare process support arise. The perspectives and limitations of IT support for healthcare processes provided the focus of three Workshops on Process-oriented Information Systems (ProHealth). These were held in conjunction with the International Conference on Business Process Management in 2007-2009. The ProHealth workshops provided a forum wherein challenges, paradigms, and tools for optimized process support in healthcare were debated. Following the success of these workshops, this special issue on process support in healthcare provides extended papers by research groups who contributed multiple times to the ProHealth workshop series. These works address issues pertaining to healthcare process modeling, process-aware healthcare information system, workflow management in healthcare, IT support for guideline implementation and medical decision support, flexibility in healthcare processes, process interoperability in healthcare and healthcare standards, clinical semantics of healthcare processes, healthcare process patterns, best practices for designing healthcare processes, and healthcare process validation, verification, and evaluation

The effect of different opacity data and chemical element mixture on the Petersen diagram

The Petersen diagram is a frequently used tool to constrain model parameters such as metallicity of radial double-mode pulsators. In this diagram the period ratio of the radial first overtone to the fundamental mode, P_1/P_0, is plotted against the period of the fundamental mode. The period ratio is sensitive to the chemical composition as well as to the rotational velocity of a star. In the present study we compute stellar pulsation models to demonstrate the sensitivity of the radial period ratio to the opacity data (OPAL and OP tables) and we also examine the effect of different relative abundances of heavy elements. We conclude that the comparison with observed period ratios could be used successfully to test the opacity data.Comment: 5 pages, 5 figures, 1 table; to be published in the Proceedings of the Conference 'Unsolved Problems in Stellar Physics', Cambridge, 2-6 July 200

Pure point diffraction implies zero entropy for Delone sets with uniform cluster frequencies

Delone sets of finite local complexity in Euclidean space are investigated. We show that such a set has patch counting and topological entropy 0 if it has uniform cluster frequencies and is pure point diffractive. We also note that the patch counting entropy is 0 whenever the repetitivity function satisfies a certain growth restriction.Comment: 16 pages; revised and slightly expanded versio

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.

OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS: In this double-blind, placebo-controlled study, 667 adults with CM were randomized (3:2:2) to placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-specific HRQoL (Migraine-Specific Quality-of-Life Questionnaire [MSQ]), headache impact (Headache Impact Test-6 [HIT-6]), migraine-related disability (Migraine Disability Assessment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement Information System [PROMIS] Pain Interference Scale short form 6b). RESULTS: Improvements were observed for all endpoints in both erenumab groups at month 3, with greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ domains were improved from baseline with treatment differences for both doses exceeding minimally important differences established for MSQ-role function-restrictive (≥3.2) and MSQ-emotional functioning (≥7.5) and for MSQ-role function-preventive (≥4.5) for erenumab 140 mg. Changes from baseline in HIT-6 scores at month 3 were -5.6 for both doses vs -3.1 for placebo. MIDAS scores at month 3 improved by -19.4 days for 70 mg and -19.8 days for 140 mg vs -7.5 days for placebo. Individual-level minimally important difference was achieved by larger proportions of erenumab-treated participants than placebo for all MSQ domains and HIT-6. Lower proportions of erenumab-treated participants had MIDAS scores of severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3. CONCLUSIONS: Erenumab-treated patients with CM experienced clinically relevant improvements across a broad range of patient-reported outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability